Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNE Sorrento Therapeutics Inc
OSUR OraSure Technologies Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
THG Hanover Insurance Group Inc
USB U.S. Bancorp
BAC Bank of America Corp
TCNNF Trulieve Cannabis Corp
RM Regional Management Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Price
Delayed
$6.93
Day's Change
-0.355 (-4.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.21
Day's Low
6.80
Volume
(Light)

Today's volume of 7,730,915 shares is on pace to be much lighter than SRNE's 10-day average volume of 12,396,051 shares.

7,730,915

Company Profile

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
53.61x
Price/Book (MRQ)
11.89x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

October 2020
Current Month
71.9M
Previous Month
75.7M
Percent of Float
32.61%
Days to Cover
4.1537 Days

Share Information

SRNE is in a share class of common stock
Float
220.4M
Shares Outstanding
261.7M
Institutions Holding Shares
220
22.94%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Henry H. JiChmn.
  • Najjam AsgharCFO
  • Dorman Followwill
  • Kim D. JandaDir.
  • Jaisim ShahDir.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.